Serum uric acid (SUA) has been suggested as a potentially modifiable mediator associated with the metabolic syndrome. Hyperuricemia and metabolic syndrome were both associated with adverse renal outcome. However, epidemiologic data are limited regarding this relationship in patients with type 2 diabetes mellitus (T2DM). This study aims to determine whether elevated SUA is associated with an increased prevalence of metabolic risk factors, albuminuria, and chronic kidney disease (CKD) in a large sample of patients with T2DM. It also examines the combined effect of SUA and metabolic syndrome components on the odds of CKD.
Methods:
A total of 1463 patients with T2DM were recruited. Blood samples were obtained to measure metabolic parameters. Patients with macroalbuminuria or an estimated glomerular filtration rate of <60 mL/min per 1.73 m2 were considered as CKD cases.
Results:
The prevalence of metabolic syndrome, central obesity, hypertension, high triglycerides (TGs), CKD, and macroalbuminuria was significantly higher in patients with hyperuricemia than those in the lowest tertile of SUA (T1). One standard deviation (SD) increment of SUA was significantly associated with metabolic syndrome, central obesity, and high TGs after adjustment for age, sex, estimated glomerular filtration rate (eGFR), and albuminuria. The odds of CKD went up to 1.37-fold with every 1 SD increment of SUA, independent of age, sex, and components of metabolic syndrome. There was a significant, graded increase in odds of CKD by increasing SUA levels and the number of metabolic syndrome risk factors (P<0.001).
Conclusion:
This study proposed a synergistic effect between SUA and metabolic syndrome components on the odds of CKD.
Get full access to this article
View all access options for this article.
References
1.
EsteghamatiA, KhalilzadehO, AnvariM, et al.The economic costs of diabetes: A population-based study in Tehran, Iran. Diabetologia, 2009; 52:1520–1527.
2.
Standards of medical care in diabetes—2012. Diabetes Care, 2012; 35(Suppl 1):S11–S63.
3.
RitzE, OrthSR.Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med, 1999; 341:1127–1133.
4.
JalalDI, MaahsDM, HovindP, et al.Uric acid as a mediator of diabetic nephropathy. Semin Nephrol, 2011; 31:459–465.
5.
SoltaniZ, RasheedK, KapustaDR, et al.Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: Is it time for reappraisal?. Curr Hypertens Rep, 2013; 15:175–181.
6.
LaguardiaHA, HammLL, ChenJ.The metabolic syndrome and risk of chronic kidney disease: Pathophysiology and intervention strategies. J Nutr Metab, 2012; 2012:652608.
7.
JohnsBR, PaoAC, KimSH.Metabolic syndrome, insulin resistance and kidney function in non-diabetic individuals. Nephrol Dial Transplant, 2011; 27:1410–1415.
8.
LukAO, SoWY, MaRC, et al.Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: A 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care, 2008; 31:2357–2361.
GrundySM, BrewerHB, CleemanJI, et al.Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 2004; 109:433–438.
11.
AlbertiKG, ZimmetP, ShawJ.Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med, 2006; 23:469–480.
12.
HovindP, RossingP, TarnowL, et al.Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: An inception cohort study. Diabetes, 2009; 58:1668–1671.
13.
KangDH, NakagawaT, FengL, et al.A role for uric acid in the progression of renal disease. J Am Soc Nephrol, 2002; 13:2888–2897.
14.
SuiX, ChurchTS, MeriwetherRA, et al.Uric acid and the development of metabolic syndrome in women and men. Metabolism, 2008; 57:845–852.
15.
ZhangML, GaoYX, WangX, et al.Serum uric acid and appropriate cutoff value for prediction of metabolic syndrome among Chinese adults. J Clin Biochem Nutr, 2013; 52:38–42.
16.
NasharK, FriedLF.Hyperuricemia and the progression of chronic kidney disease: Is uric acid a marker or an independent risk factor?. Adv Chronic Kidney Dis, 2012; 19:386–391.
17.
ZoppiniG, TargherG, ChoncholM, et al.Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care, 2012; 35:99–104.
18.
SeeLC, KuoCF, ChuangFH, et al.Hyperuricemia and metabolic syndrome: Associations with chronic kidney disease. Clin Rheumatol, 2010; 30:323–330.
19.
MatthewsDR, HoskerJP, RudenskiAS, et al.Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985; 28:412–419.
20.
ChenLY, ZhuWH, ChenZW, et al.Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B, 2007; 8:593–598.
21.
GoncalvesJP, OliveiraA, SeveroM, et al.Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine, 2012; 41:450–457.
22.
LinWY, LiuCS, LiTC, et al.In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: A population-based study (Taichung Community Health Study). Ann Rheum Dis, 2008; 67:432–433.
23.
ChoiHK, FordES.Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med, 2007; 120:442–447.
PacificoL, CantisaniV, AnaniaC, et al.Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. Eur J Endocrinol, 2009; 160:45–52.
26.
YangT, ChuCH, BaiCH, et al.Uric acid level as a risk marker for metabolic syndrome: A Chinese cohort study. Atherosclerosis, 2011; 220:525–531.
27.
LohsoonthornV, DhanamunB, WilliamsMA.Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res, 2006; 37:883–889.
28.
HongoM, HidakaH, SakaguchiS, et al.Association between serum uric acid levels and cardiometabolic risk factors among Japanese junior high school students. Circ J, 2010; 74:1570–1577.
29.
HairongN, ZengchangP, ShaojieW, et al.Serum uric acid, plasma glucose and diabetes. Diab Vasc Dis Res, 2010; 7:40–46.
30.
KawamotoR, TabaraY, KoharaK, et al.Serum uric acid is more strongly associated with impaired fasting glucose in women than in men from a community-dwelling population. PLoS One, 2013; 8:e65886.
31.
LiuPW, ChangTY, ChenJD.Serum uric acid and metabolic syndrome in Taiwanese adults. Metabolism, 2010; 59:802–807.
32.
FurukawaS, FujitaT, ShimabukuroM, et al.Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest, 2004; 114:1752–1761.
33.
TsouliSG, LiberopoulosEN, MikhailidisDP, et al.Elevated serum uric acid levels in metabolic syndrome: An active component or an innocent bystander?. Metabolism, 2006; 55:1293–1301.
34.
ReimannM, SchutteAE, MalanL, et al.Hyperuricaemia is an independent factor for the metabolic syndrome in a sub-Saharan African population: A factor analysis. Atherosclerosis, 2008; 197:638–645.
35.
DaiX, YuanJ, YaoP, et al.Association between serum uric acid and the metabolic syndrome among a middle- and old-age Chinese population. Eur J Epidemiol, 2013; 28:669–676.
36.
TsengCH.Correlation of uric acid and urinary albumin excretion rate in patients with type 2 diabetes mellitus in Taiwan. Kidney Int, 2005; 68:796–801.
37.
RodillaE, Perez-LahigueraF, CostaJA, et al.Association between serum uric acid, metabolic syndrome and microalbuminuria in previously untreated essential hypertensive patients. Med Clin (Barc), 2009; 132:1–6.
38.
TannerRM, BrownTM, MuntnerP.Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease. Curr Hypertens Rep, 2012; 14:152–159.
39.
TsioufisC, ChatzisD, VezaliE, et al.The controversial role of serum uric acid in essential hypertension: Relationships with indices of target organ damage. J Hum Hypertens, 2005; 19:211–217.
40.
ViazziF, ParodiD, LeonciniG, et al. Serum uric acid and target organ damage in primary hypertension. Hypertension, 2005; 45:991–996.
41.
IsekiK, OshiroS, TozawaM, et al.Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res, 2001; 24:691–697.
42.
JalalDI, RivardCJ, JohnsonRJ, et al.Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: Findings from the Coronary Artery Calcification in Type 1 Diabetes study. Nephrol Dial Transplant, 2010; 25:1865–1869.
43.
KanbayM, HuddamB, AzakA, et al.A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol, 2011; 6:1887–1894.
44.
YelkenB, CaliskanY, GorguluN, et al.Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clin Nephrol, 2012; 77:275–282.
45.
KlausenKP, ParvingHH, ScharlingH, et al.The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: Impact on cardiovascular disease and mortality. J Intern Med, 2007; 262:470–478.
